Currently out of the existing stock ratings of Mitchell Kapoor, 232 are a BUY (87.88%), 24 are a HOLD (9.09%), 8 are a SELL (3.03%).

Mitchell Kapoor

Work Performance Price Targets & Ratings Chart

Analyst Mitchell Kapoor, carries an average stock price target met ratio of 38.3% that have a potential upside of 32.16% achieved within 59 days. Previously, Mitchell Kapoor worked at HC WAINWRIGHT.

Mitchell Kapoor’s has documented 520 price targets and ratings displayed on 25 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on CRSP, Crispr Therapeutics AG at 07-Aug-2025.

Wall Street Analyst Mitchell Kapoor

Analyst best performing recommendations are on SMMT (SUMMIT THERAPEUTICS PLC).
The best stock recommendation documented was for SMMT (SUMMIT THERAPEUTICS PLC) at 9/9/2024. The price target of $30 was fulfilled within 4 days with a profit of $10.86 (56.74%) receiving and performance score of 141.85.

Average potential price target upside

of $38.3 (55.85%) on RPHM (RENEO PHARMACEUTICALS).
of $35.11 (30.37%) on SRPT (SAREPTA THERAPEUTICS).
of $22.44 (53.61%) on CRSP (CRISPR THERAPEUTICS AG).

IMGO Imago Biosciences IPSC Century Therapeutics LEGN Legend Biotech Corp LYEL Lyell Immunopharma RAIN Rain Therapeutics RANI Rani Therapeutics Holdings TYRA Tyra Biosciences HALO Halozyme Therapeutics RLYB Rallybio Corp RPHM Reneo Pharmaceuticals TIL Instil Bio CRSP Crispr Therapeutics AG SRPT Sarepta Therapeutics VERV Verve Therapeutics CTMX CytomX Therapeutics ALMS Alumis Common Stock KRRO Frequency Therapeutics KYTX Kyverna Therapeutics, Common Stock LXEO Lexeo Therapeutics, Common Stock MGX Metagenomi, Common Stock NGNE Neurogene ORKA Oruka Therapeutics RNAC Cartesian Therapeutics SMMT Summit Therapeutics PLC TCBP TC BioPharm Holdings PLC

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Stephen Willey (STIFEL)